|
|
|
The IMF is pleased to present the most comprehensive coverage of the XIth International Myeloma Workshop.
|
|
|
|
|
Paul Richardson, MD
Medical Oncology
Dana Farber Cancer Institute
Harvard Medical School
Boston, MA, USA
|
|
|
|
|
Donna Weber, MD
The University of Texas MD Anderson Cancer Center
Houston, TX, USA
|
|
|
|
|
Heinz Ludwig, MD
Department of Medicine I
Center of Oncology and Hematology
Wilhelminenspital
Vienna, Austria
|
|
|
|
|
Philip Greipp, MD
Mayo Clinic
Internal Medicine
Rochester, Minnesota
|
|
|
|
|
Michele Cavo, MD
Seràgnoli Institute of Hematology and Medical Oncology
Bologna UniversitySchool of Medicine
Italy
|
|
|
|
|
Sundar Jagannath, MD
St. Vincent's Comprehensive Cancer Center
New York, NY, USA
|
|
|
|
|
Vincent Rajkumar, MD
Division of Hematology
Mayo Clinic
Rochester, Minnesota, USA
|
|
|
|
|
Thierry Facon, MD
CHU
Lille, France
|
|
|
|
|
Mohamad Hussein, MD
Multiple Myeloma Clinical Research Clinical Director
H. Lee Moffitt Cancer & Research Institute
Tampa, Florida, USA
|
|
|
|
|
Joan Bladé
Hematology Department
Institut of Hematology and Oncology
IDIBAPS, HospitalClínic
Barcelona, Spain
|
|
|
print
KOS 2007: The Treatment of Relapsed and Refractory Myeloma: Focus on Bortezomib and Bortezomib-based Combinations 
KOS 2007: Lenalidomide for the Treatment of Relapsed or Refractory Myeloma 
KOS 2007: Impact of novel agents in patients with poor prognosis myeloma defined by unfavorable cytogenetics, high age, and renal failure 
KOS 2007: International Staging System for Multiple Myeloma 
KOS 2007: The Role of Thalidomide in Myeloma Patients Eligible for High-Dose Therapy 
KOS 2007: Role of Bortezomib in Myeloma Patients Eligible for High-Dose Therapy 
KOS 2007: The Role of Lenalidomide in Myeloma Patients Eligible for High Dose Therapy 
KOS 2007: Frontline Treatment in Patients Not Eligible for Stem Cell Transplant 
KOS 2007: Management of Toxicities from Novel Agents 
KOS 2007: Prognostic Factors for Multiple Myeloma in the Era of Novel Therapies 
back to top